It has been over four years since 18-year-old Jesse Gelsinger died while participating in a gene therapy experiment at the University. And in those years, the incident has served as both a catalyst ...

“That’s how they got to Jesse Gelsinger, one of the most famous names in clinical trials,” Caplan said. The trial was not intended to cure the 18-year-old volunteer; it was meant to save babies with ...

Science of gene therapy is making quiet steady progress despite questions raised by death last fall of 18-year-old Jesse Gelsinger, who was participating in trial at University of Pennsylvania; ...

The Recombinant DNA Advisory Committee (RAC) meeting in Washington, D.C., Dec. 8-10 delved into every aspect of Jesse Gelsinger's death. Gelsinger, a teenager from Arizona, had ornithine ...

In the aftermath of 18-year-old Jesse Gelsinger's death last September during a University of Pennsylvania gene therapy trial, intensified regulation of such studies will be a major topic at the ...

The University of Pennsylvania announced yesterday that it had reached an out-of-court settlement with the family of Jesse Gelsinger, the Tucson teenager whose death in a gene therapy experiment ...

In 1999, a teenager from Tucson named Jesse Gelsinger died in a gene therapy trial at Penn. Jesse’s father, Paul, shares Jesse's story.

A closely watched lawsuit filed by the family of an Arizona teenager who died after receiving an experimental gene-therapy treatment at the University of Pennsylvania ended in a settlement on Friday.